Research Groups

Mechanisms of Carcinogenesis - Molecular Mechanisms and Biomarkers Group

Previous Publications - All publications 2016-2012

1. Bouaoun L., Sonkin D., Ardin M., Hollstein M., Byrnes G., Zavadil J., Olivier M. (2016) TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data Hum Mutat; 37(9):865-76. PMID: 27328919

2. Fernandez-Cuesta L., Perdomo S., Avogbe P. H., Leblay N., Delhomme T. M., Gaborieau V., Abedi-Ardekani B., Chanudet E., Olivier M., Zaridze D., Mukeria A., Vilensky M., Holcatova I., Polesel J., Simonato L., Canova C., Lagiou P., Brambilla C., Brambilla E., Byrnes G., Scelo G., Le Calvez-Kelm F., Foll M., McKay J. D., Brennan P. (2016) Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer EBioMedicine; 117-23. PMID: 27377626

3. He S., Limi S., McGreal R. S., Xie Q., Brennan L. A., Kantorow W. L., Kokavec J., Majumdar R., Hou H. Jr., Edelmann W., Liu W., Ashery-Padan R., Zavadil J., Kantorow M., Skoultchi A. I., Stopka T., Cvekl A. (2016) Chromatin remodeling enzyme Snf2h regulates embryonic lens differentiation and denucleation Development; 143(11):1937-47. PMID: 27246713

4. Tissot C., Villar S., Olivier M., Couraud S. (2016) [Free circulating DNA as a tool for lung cancer patients management] Rev Pneumol Clin; 72(1):61-71. PMID: 26190335

5. Ardin M., Cahais V., Castells X., Bouaoun L., Byrnes G., Herceg Z., Zavadil J., Olivier M. (2016) MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes BMC Bioinformatics; 170. PMID: 27091472

6. Vojtechova Z., Sabol I., Salakova M., Smahelova J., Zavadil J., Turek L., Grega M., Klozar J., Prochazka B., Tachezy R. (2016) Comparison of the miRNA profiles in HPV-positive and HPV-negative tonsillar tumors and a model system of human keratinocyte clones BMC cancer; 382. PMID: 27377959

7. Castells X., Karanovic S., Ardin M., Tomic K., Xylinas E., Durand G., Villar S., Forey N., Le Calvez-Kelm F., Voegele C., Karlovic K., Misic M., Dittrich D., Dolgalev I., McKay J., Shariat S. F., Sidorenko V. S., Fernandes A., Heguy A., Dickman K. G., Olivier M., Grollman A. P., Jelakovic B., Zavadil J. (2015) Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid Cancer Epidemiol Biomarkers Prev; 24(12):1873-81. PMID: 26383547

8. Tissot C., Toffart A. C., Villar S., Souquet P. J., Merle P., Moro-Sibilot D., Perol M., Zavadil J., Brambilla C., Olivier M., Couraud S. (2015) Circulating free DNA concentration is an independent prognostic biomarker in lung cancer Eur Respir J; 46(6):1773-80. PMID: 26493785

9. Jelakovic B., Castells X., Tomic K., Ardin M., Karanovic S., Zavadil J. (2015) Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid Int. J Cancer; 136(12):2967-2972.

10. Krais A.M., Muhlbauer K.R., Kucab J.E., Chinbuah H., Cornelius M.G., Wei Q.X., Hollstein M., Phillips D.H., Arlt V.M., Schmeiser H.H. (2015) Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts Toxicol In Vitro; 29(1):34-43. PMID: 25230394

11. Mariga A., Zavadil J., Ginsberg S.D., Chao M.V. (2015) Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function Dev. Neurobiol; 75(2):173-192. PMID: 25059794

12. Ose J., Fortner R.T., Rinaldi S., Schock H., Overvad K., Tjonneland A., Hansen L., Dossus L., Fournier A., Baglietto L., Romieu I., Kuhn E., Boeing H., Trichopoulou A., Lagiou P., Trichopoulos D., Palli D., Masala G., Sieri S., Tumino R., Sacerdote C., Mattiello A., Ramon Quiros J., Obon-Santacana M., Larranaga N., Chirlaque M.D., Sanchez M.J., Barricarte A., Peeters P.H., Bueno-de-Mesquita H.B., Onland-Moret N.C., Brandstedt J., Lundin E., Idahl A., Weiderpass E., Gram I.T., Lund E., Kaw K.T., Travis R.C., Merritt M.A., Gunther M.J., Riboli E., Kaaks R. (2015) Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition Int. J Cancer; 136(2):399-410.

13. Ose J., Fortner R.T., Schock H., Peeters P.H., Onland-Moret N.C., Bueno-de-Mesquita H.B., Weiderpass E., Gram I.T., Overvad K., Tjonneland A., Dossus L., Fournier A., Baglietto L., Trichopoulou A., Benetou V., Trichopoulos D., Boeing H., Masala G., Krogh V., Matiello A., Tumino R., Popovic M., Obon-Santacana M., Larranaga N., Ardanaz E., Sanchez M., Menendez V., Chirlaque M., Travis R.C., Khaw K., Brandstedt J., Idahl A., Lundin E., Rinaldi S., Kuhn E., Romieu I., Gunter M.J., Merritt M.A., Riboli E., Kaaks R. (2015) Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort Br J Cancer; 112(1):162-166. PMID: 25349976

14. Tissot C., Toffart A.C., Villar S., Souquet P.J., Merle P., Moro-Sibilot D., Perol M., Zavadil J., Brambilla C., Olivier M., Couraud S. (2015) Assessment of circulating free DNA concentration as a prognostic and predictive biomarker in a large cohort of non-small cell lung cancer treated by platinum-based chemotherapy. Journal of clinical oncology; 33(15):Suppl. Abstract: 110.

15. Traore F., Gormally E., Villar S., Friesen M. D., Groopman J. D., Vernet G., Diallo S., Hainaut P., Maiga M. Y. (2015) Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali BMC Infect Dis; 180. PMID: 25886382

16. Vaca-Paniagua F., Alvarez-Gomez R.M., Maldonado-Martinez H.A., Perez-Plasencia C., Fragoso-Ontiveros V., Lasa-Gonsebatt F., Herrera L.A., Cantu D., Bargallo-Rocha E., Mohar A., Durand G., Forey N., Voegele C., Vallee M., Le Calvez-Kelm F., McKay J., Ardin M., Villar S., Zavadil J., Olivier M. (2015) Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues PLoS. One; 10(5):e0126762. PMID: 25961742

17. Vaca-Paniagua F., Oliver J., Nogueira da Costa A., Merle P., McKay J., Herceg Z., Holmila R. (2015) Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing Epigenomics; 7(3):353-362. PMID: 26077425

18. Wild C., Brennan P., Plummer M., Bray F., Straif K., Zavadil J. (2015) Cancer risk: role of chance overstated Science; 347(6223):728. PMID: 25656657

19. SEQC/MAQC-III Consortium (2014) A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium Nat Biotechnol; 32(9):903-914.

20. Cortot A.B., Younes M., Martel-Planche G., Guibert B., Isaac S., Souquet P.J., Commo F., Girard P., Fouret P., Brambilla E., Hainaut P., Soria J.C. (2014) Mutation of TP53 and Alteration of p14(arf) Expression in EGFR- and KRAS-mutated lung adenocarcinomas. Clin Lung Cancer; 15(2):124-130.

21. Couraud S., Vaca-Paniagua F., Villar S., Oliver J., Schuster T., Blanche H., Girard N., Tredaniel J., Guilleminault L., Gervais R., Prim N., Vincent M., Margery J., Larive S., Foucher P., Duvert B., Vallee M., Le Calvez-Kelm F., McKay J., Missy P., Morin F., Zalcman G., Olivier M., Souquet P.J. (2014) Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 Clin Cancer Res; 20(17):4613-4624.

22. Dai Y., Cros M.P., Pontoizeau C., Elena-Hermann B., Bonn G.K., Hainaut P. (2014) Downregulation of transcription factor E4F1 in hepatocarcinoma cells: HBV-dependent effects on autophagy, proliferation and metabolism Carcinogenesis; 35(3):635-650.

23. Giacomazzi J., Graudenz M.S., Osorio C.A., Koehler-Santos P., Palmero E.I., Zagonel-Oliveira M., Michelli R.A., Neto C.S., Fernandes G.C., Achatz M.I., Martel-Planche G., Soares F.A., Caleffi M., Goldim J.R., Hainaut P., Camey S.A., Ashton-Prolla P. (2014) Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil PLoS ONE; 9(6):e99893.

24. Izetti P., Hautefeuille A., Abujamra A.L., de Farias C.B., Giacomazzi J., Alemar B., Lenz G., Roesler R., Schwartsmann G., Osvaldt A.B., Hainaut P., Ashton-Prolla P. (2014) PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines Invest New Drugs; 32(5):783-794.

25. Karanovic S., Tomic K., Dittrich D., Borovecki F., Zavadil J., Vukovic-Lela I., Karlovic K., Knezevic M., Jelakovic B. (2014) Endemic (Balkan) nephropathy is aristolochic acid nephropathy Prilozi; 35(1):43-46.

26. Ma X., Rousseau V., Sun H., Lantuejoul S., Filipits M., Pirker R., Popper H., Mendiboure J., Vataire A.L., Le Chevalier T., Soria J.C., Brambilla E., Dunant A., Hainaut P. (2014) Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer Mol. Oncol; 8(3):555-564.

27. Mimoso C., Lee D.D., Zavadil J., Tomic-Canic M., Blumenberg M. (2014) Analysis and meta-analysis of transcriptional profiling in human epidermis Methods Mol. Biol; 61-97.

28. Olivier M., Weninger A., Ardin M., Huskova H., Castells X., Vallee M.P., McKay J., Nedelko T., Muehlbauer K.R., Marusawa H., Alexander J., Hazelwood L., Byrnes G., Hollstein M., Zavadil J. (2014) Modelling mutational landscapes of human cancers in vitro Sci Rep; 4482.

29. Sagne C., Marcel V., Bota M., Martel-Planche G., Nobrega A., Palmero E.I., Perriaud L., Boniol M., Vagner S., Cox D.G., Chan C.S., Mergny J.L., Olivier M., Ashton-Prolla P., Hall J., Hainaut P., Achatz M.I. (2014) Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures Carcinogenesis; 35(4):807-815.

30. Scelo G., Riazalhosseini Y., Greger L., Letourneau L., Gonzalez-Porta M., Wozniak M.B., Bourgey M., Harnden P., Egevad L., Jackson S.M., Karimzadeh M., Arseneault M., Lepage P., How-Kit A., Daunay A., Renault V., Blanche H., Tubacher E., Sehmoun J., Viksna J., Celms E., Opmanis M., Zarins A., Vasudev N.S., Seywright M., Abedi-Ardekani B., Carreira C., Selby P.J., Cartledge J.J., Byrnes G., Zavadil J., Su J., Holcatova I., Brisuda A., Zaridze D., Moukeria A., Foretova L., Navratilova M., Mates D., Jinga V., Artemov A., Nedoluzhko A., Mazur A., Rastorguev S., Boulygina E., Heath S., Gut M., Bihoreau M.T., Lechner D., Foglio M., Gut I.G., Skryabin K., Prokhortchouk E., Cambon-Thomsen A., Rung J., Bourque G., Brennan P., Tost J., Banks R.E., Brazma A., Lathrop G.M. (2014) Variation in genomic landscape of clear cell renal cell carcinoma across Europe Nat Commun; 5135.

31. Zavadil J. (2014) Multi-'Omics Approaches to Environmental Cancer Risk Factors: A Spotlight on Exposure to Aristolochic Acid and Its Biological Consequences Environ Mol Mutagen; S23 (S15).

32. Dichtel-Danjoy M.L., Ma D., Dourlen P., Chatelain G., Napoletano F., Robin M., Corbet M., Levet C., Hafsi H., Hainaut P., Ryoo H.D., Bourdon J.C., Mollereau B. (2013) Drosophila p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation Cell Death. Differ; 20(1):108-116.

33. Fye H.K., Wright-Drakesmith C., Kramer H.B., Camey S., Nogueira da Costa A., Jeng A., Bah A., Kirk G.D., Sharif M.I., Ladep N.G., Okeke E., Hainaut P., Taylor-Robinson S.D., Kessler B.M., Mendy M.E. (2013) Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations PLoS. One; 8(7):e68381.

34. Hafsi H., Santos-Silva D., Courtois-Cox S., Hainaut P. (2013) Effects of Delta40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53 BMC. Cancer; 134.

35. Hainaut P. (2013) TP53: coordinator of the processes that underlie the hallmarks of cancer ; 1-23.

36. Hainaut P., Olivier M., Wiman K.G. (2013) P53 in the Clinics ; .

37. Hollstein M., Moriya M., Grollman A.P., Olivier M. (2013) Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid Mutat. Res; 753(1):41-49.

38. Langerod A., Olivier M., Borresen-Dale A.L. (2013) ; 147-165.

39. Lu X., Wontakal S.N., Kavi H., Kim B.J., Guzzardo P.M., Emelyanov A.V., Xu N., Hannon G.J., Zavadil J., Fyodorov D.V., Skoultchi A.I. (2013) Drosophila H1 regulates the genetic activity of heterochromatin by recruitment of Su(var)3-9 Science; 340(6128):78-81.

40. Olivier M. (2013) TP53 somatic mutations: prognostic and predictive value in human cancers ; 127-146.

41. Ortiz-Cuaran S., Cox D., Villar S., Friesen M.D., Durand G., Chabrier A., Khuhaprema T., Sangrajrang S., Ognjanovic S., Groopman J.D., Hainaut P., Le Calvez-Kelm F. (2013) Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma Genes Chromosomes. Cancer; 52(10):912-919.

42. Ortiz-Cuaran S., Villar S., Gouas D., Ferro G., Plymoth A., Khuhaprema T., Kalalak A., Sangrajrang S., Friesen M.D., Groopman J.D., Hainaut P. (2013) Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand Cancer Lett; 331(1):46-51.

43. Sagne C., Marcel V., Amadou A., Hainaut P., Olivier M., Hall J. (2013) A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects Cell Death. Dis; e492.

44. Shepherd F.A., Domerg C., Hainaut P., Janne P.A., Pignon J.P., Graziano S., Douillard J.Y., Brambilla E., Le Chevalier T., Seymour L., Bourredjem A., Le Teuff G., Pirker R., Filipits M., Rosell R., Kratzke R., Bandarchi B., Ma X., Capelletti M., Soria J.C., Tsao M.S. (2013) Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy J Clin Oncol; 31(17):2173-2181.

45. Sighoko D., Kamate B., Traore C., Malle B., Coulibaly B., Karidiatou A., Diallo C., Bah E., McCormack V., Muwonge R., Bourgeois D., Gormally E., Curado M.P., Bayo S., Hainaut P. (2013) Breast cancer in pre-menopausal women in West Africa: analysis of temporal trends and evaluation of risk factors associated with reproductive life Breast; 22(5):828-835.

46. Abedi-Ardekani B., Dar N.A., Mir M.M., Zargar S.A., Lone M.M., Martel-Planche G., Villar S., Mounawar M., Saidi F., Malekzadeh R., Hainaut P. (2012) Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia BMC. Cancer; 602.

47. Blandino G., Deppert W., Hainaut P., Levine A., Lozano G., Olivier M., Rotter V., Wiman K., Oren M. (2012) Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop Cell Death Differ; 19(1):180-183.

48. de Fraipont F., Levallet G., Creveuil C., Bergot E., Beau-Faller M., Mounawar M., Richard N., Antoine M., Rouquette I., Favrot M.C., Debieuvre D., Braun D., Westeel V., Quoix E., Brambilla E., Hainaut P., Moro-Sibilot D., Morin F., Milleron B., Zalcman G. (2012) An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial Clin Cancer Res; 18(10):2976-2986.

49. Fernandez-Cuesta L., Oakman C., Falagan-Lotsch P., Smoth K.S., Quinaux E., Buyse M., Dolci M.S., Azambuja E.D., Hainaut P., Dell'orto P., Larsimont D., Francis P.A., Crown J., Piccart-Gebhart M., Viale G., Leo A.D., Olivier M. (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial Breast Cancer Res; 14(3):R70.

50. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., Zwolinska A., Haupt S., de Lange J., Yip D., Goydos J., Haigh J.J., Haupt Y., Larue L., Jochemsen A., Shi H., Moriceau G., Lo R.S., Ghanem G., Shackleton M., Bernal F., Marine J.C. (2012) MDM4 is a key therapeutic target in cutaneous melanoma Nat Med; 18(8):1239-1247.

51. Gouas D.A., Villar S., Ortiz-Cuaran S., Legros P., Ferro G., Kirk G.D., Lesi O.A., Mendy M., Bah E., Friesen M.D., Groopman J., Chemin I., Hainaut P. (2012) TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia Carcinogenesis; 33(6):1219-1224.

52. Hainaut P., Plymoth A. (2012) Cancer as a metabolic disease Curr Opin Oncol; 24(1):56-57.

53. Ognjanovic S., Martel G., Manivel C., Olivier M., Langer E., Hainaut P. (2012) Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma Sarcoma; 492086.

54. Scoccianti C., Vesin A., Martel G., Olivier M., Brambilla E., Timsit J.F., Tavecchio L., Brambilla C., Field J.K., Hainaut P. (2012) Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Eur Respir J; 40(1):177-184.

55. Shang S., Plymoth A., Ge S., Feng Z., Rosen H.R., Sangrajrang S., Hainaut P., Marrero J.A., Beretta L. (2012) Identification of osteopontin as a novel marker for early hepatocellular carcinoma Hepatology; 55(2):483-490.

56. Villar S., Ortiz-Cuaran S., Abedi-Ardekani B., Gouas D., Nogueira da Costa A., Plymoth A., Khuhaprema T., Kalalak A., Sangrajrang S., Friesen M.D., Groopman J.D., Hainaut P. (2012) Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis PLoS ONE; 7(6):e37707.